Draft Guidance Comments: RRAs Beneficial, But Need More Explanation

The FDA questioned and answered virtually all aspects of Remote Regulatory Assessments (RRA) in an 18-page revised draft guidance issued last January, and the comments on the Q&A document have arrived with more questions of their own.
Source: Drug Industry Daily